A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy

Overview of attention for article published in Breast Cancer Research, July 2019

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users
patent: 1 patent

facebook: 1 Facebook page

Citations

dimensions_citation: 49 Dimensions

Readers on

mendeley: 72 Mendeley

Summary X Patents Facebook Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 2,463 followers.

A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted ... https://t.co/voEOa5B8rv

17 Jun 2020

Reply Repost Favourite

New from #ERC_Research https://t.co/M6qxnYWbnX A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy

14 Jul 2019

Reply Repost Favourite

Dual inhibition of cdc7 and CDK9 by PHA-767491 is a potential strategy for targeting Triple Negative Breast Cancer, resistant to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Reference; https://t.co/QpdJ3H5YkZ

03 Jul 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.